Documents
Application Sponsors
ANDA 210924 | TEVA PHARMS USA INC | |
Marketing Status
None (Tentative Approval) | 001 |
None (Tentative Approval) | 002 |
None (Tentative Approval) | 003 |
Application Products
001 | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 8.6MG | 0 | METHYLPHENIDATE | METHYLPHENIDATE |
002 | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 17.3MG | 0 | METHYLPHENIDATE | METHYLPHENIDATE |
003 | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 25.9MG | 0 | METHYLPHENIDATE | METHYLPHENIDATE |
FDA Submissions
UNKNOWN; | ORIG | 1 | TA | 2018-12-20 | STANDARD |
Submissions Property Types
TE Codes
001 | Prescription | AB |
002 | Prescription | AB |
003 | Prescription | AB |
CDER Filings
ACTAVIS ELIZABETH
cder:Array
(
[0] => Array
(
[ApplNo] => 210924
[companyName] => ACTAVIS ELIZABETH
[docInserts] => ["",""]
[products] => [{"drugName":"METHYLPHENIDATE","activeIngredients":"METHYLPHENIDATE","strength":"8.6MG","dosageForm":"TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"METHYLPHENIDATE","activeIngredients":"METHYLPHENIDATE","strength":"17.3MG","dosageForm":"TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"METHYLPHENIDATE","activeIngredients":"METHYLPHENIDATE","strength":"25.9MG","dosageForm":"TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"06\/19\/2020","submission":"ORIG-1","actionType":"Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/210924Orig1s000ltr.pdf\"}]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2020-06-19
)
)